|
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $1.24 | $1.30 | +5.1% |
| Q4'25 | $1.15 | $1.46 | +27.0% |
| Q4'24 | $1.05 | $1.15 | +9.2% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $1.3B | $925M | -26.6% |
| Q4'25 | $859M | $874M | +1.7% |
| Q4'24 | - | $742M | - |
Market Data
RPRX is currently trading at $52.47, giving RPRX a market cap of 26.02B and a P/E ratio of 34.0. Today's range spans $44.71–$45.91, with shares opening at $44.84 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY) with a news sentiment reading of 68/100.
Over the past year RPRX has traded between $29.66 and $45.91 - the current price is +76.9% off the 52-week low and +14.3% from the high.
Growth-oriented Healthcare investors looking for technical confirmation find it in RPRX: BUY signal, 95/100 score, bullish sentiment at 68/100, price $52.47 (near 52-week highs). The current P/E ratio stands at 34.0. The 26.02B market cap is the sweet spot - big enough to absorb institutional sizing, small enough to move materially on conviction. Annual range: $29.66–$45.91.
Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (95/100) and news sentiment (68/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $52.47 (near 52-week highs), RPRX's position within the $29.66–$45.91 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Most recent articles, ranked by recency (click to expand).
Sentiment gathered from recent headlines